- Home
- VG vs ONC Comparison
VG vs ONC Comparison
Compare VG & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VG
- ONC
- Stock Information
- Founded
- VG 2013
- ONC 2010
- Country
- VG United States
- ONC Switzerland
- Employees
- VG N/A
- ONC N/A
- Industry
- VG
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- VG
- ONC Health Care
- Exchange
- VG NYSE
- ONC Nasdaq
- Market Cap
- VG 28.5B
- ONC 26.9B
- IPO Year
- VG 2025
- ONC N/A
- Fundamental
- Price
- VG $15.02
- ONC $243.26
- Analyst Decision
- VG Buy
- ONC Strong Buy
- Analyst Count
- VG 11
- ONC 9
- Target Price
- VG $16.27
- ONC $325.56
- AVG Volume (30 Days)
- VG 7.5M
- ONC 363.0K
- Earning Date
- VG 08-06-2025
- ONC 08-06-2025
- Dividend Yield
- VG 0.44%
- ONC N/A
- EPS Growth
- VG N/A
- ONC N/A
- EPS
- VG 0.47
- ONC N/A
- Revenue
- VG $6,452,000,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- VG $166.11
- ONC $869.15
- Revenue Next Year
- VG $16.44
- ONC $19.07
- P/E Ratio
- VG $31.58
- ONC N/A
- Revenue Growth
- VG 0.06
- ONC 51.16
- 52 Week Low
- VG $6.75
- ONC $142.00
- 52 Week High
- VG $25.50
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- VG N/A
- ONC N/A
- Support Level
- VG N/A
- ONC N/A
- Resistance Level
- VG N/A
- ONC N/A
- Average True Range (ATR)
- VG 0.00
- ONC 0.00
- MACD
- VG 0.00
- ONC 0.00
- Stochastic Oscillator
- VG 0.00
- ONC 0.00
About VG VENTURE GLOBAL INC
Venture Global operates two liquified natural gas, or LNG, production facilities in Louisiana. It has pioneered the use of smaller, factory-built equipment producing unexpectedly high yields. With a substantial development plan, it seeks to become a vertically integrated LNG producer and supplier to end consumers around the world.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.